Praecis, Schering deal

SCH licensed rights to commercialize PRCS's Plenaxis abarelix to treat prostate cancer in Europe, Russia, the Middle East, South Africa and New Zealand. PRCS will receive an upfront payment and is eligible for milestones. PRCS also will receive shared revenues through volume-based transfer payments for the product, which it will supply to SCH. ...